Target Group Inc (CBDY)
0.0050
0.00 (0.00%)
USD |
OTCM |
May 17, 09:37
Target Group Enterprise Value: 2.310M for May 17, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| May 17, 2024 | 2.310M |
| May 16, 2024 | 2.896M |
| May 15, 2024 | 2.773M |
| May 14, 2024 | 2.587M |
| May 13, 2024 | 2.587M |
| May 10, 2024 | 1.107M |
| May 09, 2024 | 1.107M |
| May 08, 2024 | 1.107M |
| May 07, 2024 | 1.107M |
| May 06, 2024 | 2.032M |
| May 03, 2024 | 1.107M |
| May 02, 2024 | 3.883M |
| May 01, 2024 | 3.945M |
| April 30, 2024 | 4.007M |
| April 29, 2024 | 4.007M |
| April 26, 2024 | 2.834M |
| April 25, 2024 | 2.557M |
| April 24, 2024 | 2.557M |
| April 23, 2024 | 2.834M |
| April 22, 2024 | 2.032M |
| April 19, 2024 | 3.698M |
| April 18, 2024 | 3.698M |
| April 17, 2024 | 3.266M |
| April 16, 2024 | 3.513M |
| April 15, 2024 | 3.513M |
| Date | Value |
|---|---|
| April 12, 2024 | 2.624M |
| April 11, 2024 | 2.624M |
| April 10, 2024 | 3.513M |
| April 09, 2024 | 2.711M |
| April 08, 2024 | 1.847M |
| April 05, 2024 | 1.316M |
| April 04, 2024 | 1.52M |
| April 03, 2024 | 1.292M |
| April 02, 2024 | 1.545M |
| April 01, 2024 | 1.526M |
| March 31, 2024 | 1.292M |
| March 28, 2024 | 1.301M |
| March 27, 2024 | 1.301M |
| March 26, 2024 | 1.517M |
| March 25, 2024 | 1.449M |
| March 22, 2024 | 1.270M |
| March 21, 2024 | 1.270M |
| March 20, 2024 | 1.610M |
| March 19, 2024 | 1.610M |
| March 18, 2024 | 1.610M |
| March 15, 2024 | 1.548M |
| March 14, 2024 | 1.610M |
| March 13, 2024 | 1.610M |
| March 12, 2024 | 1.610M |
| March 11, 2024 | 0.9307M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-0.0595M
Minimum
Jul 14 2023
60.30M
Maximum
Aug 21 2019
9.132M
Average
5.579M
Median
Oct 15 2020
Enterprise Value Benchmarks
| Acasti Pharma Inc | 0.1704M |
| Aurinia Pharmaceuticals Inc | 473.30M |
| Edesa Biotech Inc | 11.83M |
| Lexaria Bioscience Corp | 35.42M |
| Xenon Pharmaceuticals Inc | 2.304B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -0.1932M |
| Revenue (Quarterly) | 1.920M |
| Total Expenses (Quarterly) | 1.800M |
| EPS Diluted (Quarterly) | -0.0003 |
| Gross Profit Margin (Quarterly) | 42.20% |
| Profit Margin (Quarterly) | -10.06% |
| Earnings Yield | 8.08% |
| Operating Earnings Yield | 0.91% |
| Normalized Earnings Yield | -36.67 |